These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22941581)

  • 21. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.
    Olivares JM; Peuskens J; Pecenak J; Resseler S; Jacobs A; Akhras KS;
    Curr Med Res Opin; 2009 Sep; 25(9):2197-206. PubMed ID: 19604073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antinuclear antibodies and lupus due to phenothiazines in 600 hospitalized patients].
    Gallien M; Schnetzler JP; Morin J
    Ann Med Psychol (Paris); 1975 Feb; 1(2):237-48. PubMed ID: 9021
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug induced dystonia tarda: treatment with L-dopa.
    Keegan DL; Rajput AH
    Dis Nerv Syst; 1973 Mar; 34(3):167-9. PubMed ID: 4146031
    [No Abstract]   [Full Text] [Related]  

  • 24. Performance of compliance and persistence measures in predicting clinical and economic outcomes using administrative data from German sickness funds.
    Frey S; Stargardt T
    Pharmacotherapy; 2012 Oct; 32(10):880-9. PubMed ID: 23033227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications.
    Novick D; Haro JM; Bertsch J; Anand H; Jemiai N; Haddad PM
    Int Clin Psychopharmacol; 2012 Sep; 27(5):275-82. PubMed ID: 22699789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Piperacetazine vs. thioridazine for the control of schizophrenia in outpatients.
    Rada RT; Donlon PT
    Psychosomatics; 1972; 13(6):373-6. PubMed ID: 4153002
    [No Abstract]   [Full Text] [Related]  

  • 28. Bilateral gynaecomastia in a Nigerian patient with schizophrenia.
    Coker AO
    Afr J Psychiatry (Johannesbg); 2010 May; 13(2):96. PubMed ID: 20473469
    [No Abstract]   [Full Text] [Related]  

  • 29. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
    Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
    Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-blind comparison of trebenzomine and thioridazine in the treatment of schizophrenia.
    Georgotas A; Gerbino L; Jordan B; McCarthy M; Gershon S; Kleinberg D; Lautin A; Stanley M; Rotrosen J
    Psychopharmacology (Berl); 1981; 73(3):292-4. PubMed ID: 6113618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mesoridazine and thioridazine: clinical effects and blood levels in refractory schizophrenics.
    Vital-Herne J; Gerbino L; Kay SR; Katz IR; Opler LA
    J Clin Psychiatry; 1986 Jul; 47(7):375-9. PubMed ID: 2873133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSM thioridazine advice.
    Driscoll P
    Br J Gen Pract; 2004 Aug; 54(505):623; author reply 623-4. PubMed ID: 15296568
    [No Abstract]   [Full Text] [Related]  

  • 34. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined therapy with thioridazine decreases plasma levels of quetiapine inTaiwanese schizophrenic patients.
    Chang SC; Lu ML; Wang YC; Lin FW; Huang SH; Kuo PH; Ho HO; Wu TH
    Ther Drug Monit; 2012 Jun; 34(3):345-8. PubMed ID: 22569350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New vs. old antipsychotics: the Texas experience.
    Reid WH
    J Clin Psychiatry; 1999; 60 Suppl 1():23-5; discussion 28-30. PubMed ID: 10037167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval.
    Dallaire S
    CMAJ; 2001 Jan; 164(1):91, 95. PubMed ID: 11202679
    [No Abstract]   [Full Text] [Related]  

  • 38. The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine.
    Preskorn SH
    J Psychiatr Pract; 2005 May; 11(3):192-6. PubMed ID: 15920392
    [No Abstract]   [Full Text] [Related]  

  • 39. Cardiotoxicity and prescription of thioridazine in New Zealand.
    Menkes DB; Knight JC
    Aust N Z J Psychiatry; 2002 Aug; 36(4):492-8. PubMed ID: 12169148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study.
    Addington DE; Jones B; Bloom D; Chouinard G; Remington G; Albright P
    Clin Ther; 1993; 15(5):917-26. PubMed ID: 7505716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.